After a median follow-up of @ months ( IQR @-@ months ) in the trastuzumab emtansine group and @ months ( IQR @-@ ) in the physician 's choice group , @ ( @ % ) patients in the trastuzumab emtansine group and @ ( @ % ) of patients in the physician 's choice group had PFS events .